Request Demo

Last update 08 May 2025

LSF

Last update 08 May 2025

Basic Info

Synonyms

Alpha-globin transcription factor CP2, CP2, LBP-1C

+ [7]

Introduction

Binds a variety of cellular and viral promoters including fibrinogen, alpha-globin, SV40 and HIV-1 promoters. Activation of the alpha-globin promoter in erythroid cells is via synergistic interaction with UBP1 (By similarity). Functions as part of the SSP (stage selector protein) complex. Facilitates the interaction of the gamma-globin genes with enhancer elements contained in the locus control region in fetal erythroid cells. Interacts by binding to the stage selector element (SSE) in the proximal gamma-globin promoter.

Drugs associated with LSF

CN118191315

Patent Mining

Target

LSF

Mechanism-

Active Org.

South China Agricultural University

Originator Org.

South China Agricultural University

Active Indication

Infectious Diseases

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

FQI-34

Target

LSF

Mechanism

LSF inhibitors

Active Org.-

Originator Org.

Boston University

Active Indication-

Inactive Indication

Colorectal Cancer [+2]

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

FQI-37

Target

LSF

Mechanism

LSF inhibitors

Active Org.-

Originator Org.

Boston University

Active Indication-

Inactive Indication

Colorectal Cancer [+2]

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with LSF

100 Translational Medicine associated with LSF

0 Patents (Medical) associated with LSF

579

Literatures (Medical) associated with LSF

01 May 2025·Journal of Neurophysiology

Convergent effects of peptides on the initiation of feeding motor programs in the mollusk Aplysia

Article

Author: Cropper, Elizabeth C. ; Patel, Paras R. ; Evans, Colin G. ; Reaver, Carrie N. ; Jing, Jian ; Barry, Michael A. ; Chestek, Cynthia A. ; Perkins, Matthew H.

The activity of most networks is affected by multiple neuromodulators. Studies that have sought to determine why this is the case have focused on how the effects of one modulator differ from those of another (how modulators uniquely determine motor output). This study differs in that we ask why a convergent (common) network modification is important. We show that it can promote program induction and present data that suggest this may have consequences for task switching.

01 May 2025·International Journal of Biological Macromolecules

Upstream-binding protein-1 promotes breast tumorigenesis by inducing NRG2-mediated metastasis, plasticity, and macrophage polarization

Article

Author: Negi, Manorma ; Kaushik, Nagendra Kumar ; Jaiswal, Apurva ; Choi, Eun Ha ; Kaushik, Neha

Upstream binding protein 1 (UBP1) is a transcription factor (TF) of the CP2/grainyhead family involved in various biological processes, including cancer cell proliferation, differentiation, and embryonic development. While other mammalian grainyhead-like TFs have been linked to different cancers, including breast cancer (BC), the role of UBP1 in BC remains unexplored. In this study, we provide a preliminary investigation into the novel functions of UBP1 in BC. Using online database screening, we first demonstrated that elevated UBP1 levels in breast carcinoma are associated with poor prognosis and adverse clinical outcomes. We further showed that UBP1 promotes epithelial-mesenchymal transition (EMT) and stemness in BC cells while regulating key signaling pathways, including the PI3K-Akt. Additionally, UBP1 modulates tumor metastasis by influencing tumor-associated macrophage (TAM) polarization, promoting an immunosuppressive macrophage phenotype, and driving tumor progression. Our findings highlight UBP1's pivotal role in BC progression through multiple mechanisms, including EMT induction, stemness maintenance, and macrophage polarization via activation of the NRG2/Akt axis. Moreover, higher UBP1 expression correlates with lower overall and recurrence-free survival, underscoring its potential as a prognostic marker and therapeutic target for aggressive BC.

16 Apr 2025·ACS Applied Materials & Interfaces

High-Performance and Low-Power Applications of n- and p-Type Symmetrically Ultrascaled Pentagonal CX₂ Transistors

Article

Author: Gao, Feng ; Zhao, Wenkai ; Yang, Chuanlu ; Xu, Yuqing ; Shan, Shunran ; Zou, Dongqing ; Liu, Yuliang

The disparity in transport properties between n-type and p-type transistors has hindered the advancement of complementary metal-oxide-semiconductor (CMOS) integrated circuits. We designed Penta-CX₂ (X = N, P, As, Sb) field-effect transistors (FETs) and utilized first-principles methods to evaluate their quantum transport characteristics. Our results demonstrate that CP₂ and CAs₂ exhibit superior transport properties and low subthreshold swing (SS) in both n-type and p-type configurations at sub-5 nm channel lengths. For high-performance (HP) applications, the on-state current (I_on) for both n-type and p-type devices exceeds 3000 μA/μm, peaking at 4574 μA/μm. In low-power (LP) applications, I_on for both types of devices surpasses 1000 μA/μm, reaching a maximum of 1735 μA/μm, significantly exceeding the International Roadmap for Devices and Systems (IRDS) standards for HP and LP applications. Furthermore, even when the channel length is reduced to 4 or 3 nm, the devices maintain exceptional performance. Additionally, we established a correlation between carrier effective mass and the saturation current, elucidating how the anisotropy of carrier effective mass influences transport properties and explaining the physical mechanisms by which the device overcomes Boltzmann's tyranny. This study provides valuable insights and references for designing advanced CMOSFETs in the post-Si era using channel materials with unique effective mass.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

LSF

Basic Info

Related

Analysis